Post by AIxBiotech

The most important thing about Lilly's new obesity pill is not the weight loss data. It is the price. The format. And the supply chain behind it. The FDA approved Foundayo on April 1, 2026. Eli Lilly (https://lnkd.in/gn5rB_r9) now has the first oral GLP-1 receptor agonist for obesity on the market. No injection. No food restrictions. Once daily. Small molecule, which means it can be manufactured at a cost and scale that injectables simply cannot match. Our team at AIxBiotech looked at what this does to the GLP-1 commercial landscape. Novo Nordisk (https://lnkd.in/eDAR2yW5) has dominated this market with Wegovy and Ozempic. Both are injectable. Both face supply constraints. Both require a cold chain. Foundayo eliminates all three friction points simultaneously. The commercial implications run deeper than the obvious competitive dynamic. Oral delivery expands the addressable patient population to include people who would not self-inject. It simplifies pharmacy distribution. It opens a direct-to-consumer channel, something Lilly is already moving toward through LillyDirect, that bypasses the traditional payer intermediary model entirely. This is not just a new product. It is a different commercial architecture for the GLP-1 category. Competing programmes that are still injectable need to decide now whether to compete on efficacy or accept that the format war has already begun. Based on publicly available information. This analysis covers non-proprietary, publicly disclosed data only. 🤖 AI x Biotech: No hype. Concrete signals for biotech executives and commercial teams. Follow @aixbiotech for daily updates — and to keep us going.